Immunocore Holdings plc
IMCR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.97 | -3.19 | 0.59 | -0.24 |
| FCF Yield | 1.42% | -0.07% | -1.55% | -12.16% |
| EV / EBITDA | -37.70 | -57.73 | -49.37 | -5.40 |
| Quality | ||||
| ROIC | -8.51% | -11.79% | -16.33% | -51.50% |
| Gross Margin | 99.12% | 99.58% | 99.68% | -174.77% |
| Cash Conversion Ratio | -0.51 | -0.07 | 0.94 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.76% | 89.79% | 68.56% | 12.43% |
| Free Cash Flow Growth | 940.56% | 92.57% | 74.41% | -105.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 6.94 | 6.86 | 1.04 |
| Interest Coverage | -3.74 | -11.57 | -7.91 | -23.17 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.23 | 0.48 | -9.64 |
| Cash Conversion Cycle | -2,529.00 | -4,590.34 | -10,788.61 | 248.36 |